A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT07037901

Public ClinicalTrials.gov record NCT07037901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Aug 4, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Study identification

NCT ID: NCT07037901
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Inmagene LLC; Industry
Enrollment: 405 participants

Conditions and interventions

Conditions

Interventions

IMG-007 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 74 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 16, 2025
Primary completion: Nov 30, 2027
Completion: Jul 31, 2028
Last update posted: May 26, 2026

2025 – 2028

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 16

Facility	City	State	ZIP	Site status
Inmagene Site 1	Lancaster	California	93534	Recruiting
Inmagene Site 23	Los Angeles	California	90095	Recruiting
Inmagene Site 19	Ocala	Florida	34470	Recruiting
Inmagene Site 4	Tampa	Florida	33609	Recruiting
Inmagene Site 2	Rolling Meadows	Illinois	60008	Recruiting
Inmagene Site 6	Kew Gardens	New York	11415	Recruiting
Inmagene Site 21	New York	New York	10029	Recruiting
Inmagene Site 11	Woodbury	New York	11797	Recruiting
Inmagene Site 20	Charlotte	North Carolina	28277	Recruiting
Inmagene Site 10	Fargo	North Dakota	58103	Recruiting
Inmagene Site 9	Columbus	Ohio	43213	Recruiting
Inmagene Site 5	Mayfield Heights	Ohio	44124	Recruiting
Inmagene Site 3	Portland	Oregon	97210	Recruiting
Inmagene Site 12	Anderson	South Carolina	29621	Recruiting
Inmagene Site 8	Southlake	Texas	76092	Recruiting
Inmagene Site 7	Burien	Washington	698168	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07037901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 26, 2026 · Synced Aug 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07037901 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →